J R Korzenik

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Case closed? Diverticulitis: epidemiology and fiber
    Joshua R Korzenik
    MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    J Clin Gastroenterol 40:S112-6. 2006
  2. pmc Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
    Xochitl C Morgan
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Genome Biol 13:R79. 2012
  3. pmc Is Crohn's disease due to defective immunity?
    J R Korzenik
    Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
    Gut 56:2-5. 2007
  4. ncbi request reprint Sargramostim for active Crohn's disease
    Joshua R Korzenik
    Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    N Engl J Med 352:2193-201. 2005
  5. ncbi request reprint Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators
    Joshua R Korzenik
    IBD Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Gastroenterol 39:S59-65. 2005
  6. ncbi request reprint An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease
    J R Korzenik
    Department of Internal Medicine, Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Aliment Pharmacol Ther 21:391-400. 2005
  7. doi request reprint Diverticulitis: new frontiers for an old country: risk factors and pathogenesis
    Joshua R Korzenik
    Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, Boston, MA 02114, USA
    J Clin Gastroenterol 42:1128-9. 2008
  8. ncbi request reprint Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab
    Joshua R Korzenik
    Gastrointestinal Unit, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114 2622, USA
    Gastroenterol Clin North Am 33:285-301, ix. 2004
  9. ncbi request reprint Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
  10. doi request reprint Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire
    Manuel Y Lam
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Inflamm Bowel Dis 15:599-607. 2009

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Case closed? Diverticulitis: epidemiology and fiber
    Joshua R Korzenik
    MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    J Clin Gastroenterol 40:S112-6. 2006
    ..This understanding, if demonstrated, would have important implications for the primary and secondary prevention of diverticulitis...
  2. pmc Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
    Xochitl C Morgan
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Genome Biol 13:R79. 2012
    ..Gene and pathway composition were assessed, based on 16S data from phylogenetically-related reference genomes, and associated using sparse multivariate linear modeling with medications, environmental factors, and IBD status...
  3. pmc Is Crohn's disease due to defective immunity?
    J R Korzenik
    Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
    Gut 56:2-5. 2007
    ..Recent advances in genetics, functional studies on innate immunity and therapeutic trials on patients with Crohn's disease have lent support to this evolving hypothesis...
  4. ncbi request reprint Sargramostim for active Crohn's disease
    Joshua R Korzenik
    Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    N Engl J Med 352:2193-201. 2005
    ..Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial...
  5. ncbi request reprint Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators
    Joshua R Korzenik
    IBD Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Gastroenterol 39:S59-65. 2005
    ..A variety of changes in the gut flora, ranging from a basic dysbiosis to the absence of helminths, have been proposed as the root cause of inflammatory bowel disease...
  6. ncbi request reprint An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease
    J R Korzenik
    Department of Internal Medicine, Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Aliment Pharmacol Ther 21:391-400. 2005
    ..Anecdotal cases using haemopoietic colony-stimulating factors report improvement in intestinal disease associated with these syndromes...
  7. doi request reprint Diverticulitis: new frontiers for an old country: risk factors and pathogenesis
    Joshua R Korzenik
    Department of Internal Medicine, Massachusetts General Hospital, MGH Crohn s and Colitis Center, Boston, MA 02114, USA
    J Clin Gastroenterol 42:1128-9. 2008
    ..Despite these evidences, the risk factors and pathophysiology progression from asymptomatic diverticular disease to diverticulitis have been inadequately studied. This subject is reviewed in more detail in this manuscript...
  8. ncbi request reprint Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab
    Joshua R Korzenik
    Gastrointestinal Unit, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114 2622, USA
    Gastroenterol Clin North Am 33:285-301, ix. 2004
    ..This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action...
  9. ncbi request reprint Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
    ..It is not known whether infliximab is an effective maintenance therapy for patients with fistulas...
  10. doi request reprint Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire
    Manuel Y Lam
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Inflamm Bowel Dis 15:599-607. 2009
    ..We assessed the validity of an interactive voice response system (IVRS) as a new mode of administering the SIBDQ...
  11. ncbi request reprint Risks and benefits of infliximab for the treatment of Crohn's disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Clin Gastroenterol Hepatol 4:1017-24; quiz 976. 2006
    ..The purpose of this study was to analyze the risks and benefits of infliximab for the treatment of Crohn's disease with the goal of providing data to aid both physicians and patients in the process of making a decision about treatment...
  12. doi request reprint Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease
    A Tinsley
    Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, NY 10029, USA
    Aliment Pharmacol Ther 34:1328-36. 2011
    ..76, 95% CI -0.89 to -0.50), CRP (-0.72, 95% CI -0.88 to -0.43) and HCT (0.53, 95% CI 0.22-0.74). CONCLUSION  The FACIT-F scale is a reliable and valid instrument for measuring fatigue in IBD...
  13. ncbi request reprint Evolving knowledge and therapy of inflammatory bowel disease
    Joshua R Korzenik
    Gastrointestinal Unit, Department of Medicine, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Nat Rev Drug Discov 5:197-209. 2006
    ..With increasing evidence for a crucial role for luminal flora in maintaining the health of the bowel, strategies to manipulate intestinal bacteria using probiotics and prebiotics are being actively investigated as well...
  14. ncbi request reprint Crohn's disease: innate immunodeficiency?
    Jesus K Yamamoto-Furusho
    Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
    World J Gastroenterol 12:6751-5. 2006
    ....
  15. ncbi request reprint Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
    Brian K Dieckgraefe
    Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St Louis, MO 63110, USA
    Lancet 360:1478-80. 2002
    ..Retreatment was effective, and treatment was associated with increased quality-of-life measures. GM-CSF may offer an alternative to traditional immunosuppression in treatment of Crohn's disease...
  16. pmc LRRK2 is involved in the IFN-gamma response and host response to pathogens
    Agnès Gardet
    Center for the Study of the Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Immunol 185:5577-85. 2010
    ..These observations indicate that LRRK2 is an IFN-γ target gene, and it might be involved in signaling pathways relevant to Crohn's disease pathogenesis...
  17. ncbi request reprint Inflammatory bowel disease and environmental influences
    Aruna Krishnan
    Department of Internal Medicine, Washington University School of Medicine, 4950 Children s Place, Box 8121, St Louis, MO 63110, USA
    Gastroenterol Clin North Am 31:21-39. 2002
    ..The conflicting evidence in many of these studies may be clarified as specific genes are identified and the interplay between these environmental factors and genetic subtypes is investigated...
  18. ncbi request reprint Growth factors as treatment options for intestinal inflammation
    Brian K Dieckgraefe
    Division of Gastroenterology, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann N Y Acad Sci 1072:300-6. 2006
    ..These data focus on the reparative components of mucosal homeostasis...
  19. ncbi request reprint Probiotics for recurrent Clostridium difficile disease
    Steven J Lawrence
    J Med Microbiol 54:905-6. 2005
  20. ncbi request reprint Association of glycogen storage disease 1b and Crohn disease: results of a North American survey
    Brian K Dieckgraefe
    Washington University School of Medicine 660 S Euclid Ave, Campus Box 8124, St Louis, MO 63110, USA
    Eur J Pediatr 161:S88-92. 2002
    ..Many patients had significant improvement or resolution of gastrointestinal disease in response to G-CSF treatment. The expression of CD in patients with GSD-1b may be delayed or prevented by G-CSF treatment...